Endometrial Cancer

On this page

Endometrial Cancer: Epi & Risks - Cancer's Guest List

  • Most common GYN malignancy (developed nations); 4th common cancer in women.
  • Peak: 55-65 yrs (postmenopausal).
  • Key Risk: Unopposed Estrogen
    • Exogenous: Estrogen Replacement Therapy (ERT) without progestin.
    • Endogenous:
      • Obesity (↑ peripheral estrone).
      • Nulliparity.
      • Early menarche (<12 yrs).
      • Late menopause (>52 yrs).
      • PCOS (chronic anovulation).
      • Estrogen-secreting tumors.
  • Other Major Risks:
    • Tamoxifen (endometrial agonist).
    • Diabetes Mellitus, Hypertension.
    • Lynch Syndrome (HNPCC).
    • Family Hx (endometrial, ovarian, breast, colon).
    • Prior pelvic radiation.

⭐ Lynch Syndrome (HNPCC) significantly ↑ endometrial cancer risk (40-60% lifetime), often preceding or co-occurring with colon cancer.

Endometrial Cancer Infographic

  • Protective: Combined Oral Contraceptives (COCs), progestins, multiparity, smoking (paradoxical).

Endometrial Cancer: Patho & Types - Tumor's ID Card

  • Precursor: Endometrial Hyperplasia (EH) → Atypical EH / Endometrial Intraepithelial Neoplasia (EIN) → Carcinoma.
    • EH without atypia: Low malignant potential.
    • Atypical EH / EIN: High risk (~30-50%) progression to carcinoma if untreated.

Endometrial hyperplasia vs carcinoma histopathology

  • Two Main Types: 📌 (Remember: Type I = Indolent/Estrogen; Type II = IIl/p53)
FeatureType I (Estrogen-Dependent)Type II (Estrogen-Independent)
Frequency~80%~10-20%
HistologyEndometrioidSerous, Clear cell, Carcinosarcoma
PathogenesisUnopposed E2, EIN precursorp53 mut, atrophy
Patient ProfilePerimenopausal, obesePostmenopausal, thin
Key MutationsPTEN, KRAS, MSI, ARID1ATP53, PPP2R1A
PrognosisBetterPoorer
- POLE ultramutated (Best prog, younger, immune "hot")
- MSI hypermutated (Good prog, Lynch, immune "hot")
- CN-low (Endometrioid, Intermediate prog)
- CN-high (Serous-like, TP53mut, Worst prog, immune "cold")

⭐ Lynch syndrome (HNPCC) significantly ↑ risk of endometrial cancer (MSI pathway), often the sentinel cancer.

Endometrial Cancer: Symptoms & Dx - Detective Work

  • Symptoms:
    • Most Common: Abnormal Uterine Bleeding (AUB).
      • Postmenopausal Bleeding (PMB): Cancer until proven otherwise.
      • Premenopausal: Irregular, heavy, or intermenstrual bleeding.
    • Less Common:
      • Serosanguinous/watery vaginal discharge.
      • Pelvic pain or pressure (advanced).
      • Pyometra (uterine pus).
  • Diagnosis:
    • Initial: Transvaginal Sonography (TVS).
      • Measures Endometrial Thickness (ET).
      • PMB: ET > 4-5 mm suspicious, requires sampling.
      • Asymptomatic PM: ET > 11 mm may need investigation.
    • Gold Standard: Endometrial Sampling.
      • Office endometrial biopsy (Pipelle).
      • Hysteroscopy + D&C if biopsy inconclusive or focal lesion.
    • Staging: MRI pelvis, CT chest/abdomen.

Transvaginal Ultrasound Procedure

⭐ Any postmenopausal bleeding mandates investigation to rule out endometrial cancer.

Endometrial Cancer: Staging & Tx - Treatment Roadmap

FIGO 2023 Staging (Simplified)

StageDescription
IConfined to corpus uteri
IANo or <50% myometrial invasion
IB50% myometrial invasion
IICervical stromal invasion
> ⭐ Stage II: Cervical stromal invasion is key.
IIILocal/regional spread (serosa, adnexa, vagina, LN)
IIICPelvic (IIIC1) or Para-aortic (IIIC2) LN mets
IVBladder/bowel mucosa (IVA) or distant mets (IVB)
  • Histologic Type (Endometrioid vs Non-endometrioid), Grade
  • Depth of myometrial invasion, LVSI
  • Lymph Node (LN) status, Molecular profile (POLE, MMRd, p53abn, NSMP)

Endometrial Cancer Molecular Classification

Simplified Treatment:

TAH+BSO: Total Hysterectomy + Bilateral Salpingo-oophorectomy; LND: Lymph Node Dissection; RT: Radiotherapy; VBT: Vaginal Brachytherapy; Rx: Therapy; EC: Endometrial Cancer.

High‑Yield Points - ⚡ Biggest Takeaways

  • Endometrial cancer is the most common gynecologic malignancy, mainly in postmenopausal women.
  • Unopposed estrogen (obesity, PCOS, tamoxifen) is the primary risk factor.
  • Postmenopausal bleeding is the hallmark symptom; requires TVUS and endometrial biopsy.
  • Type 1 (endometrioid): common (80%), estrogen-dependent, good prognosis.
  • Type 2 (serous/clear cell): aggressive, p53 mutation, poorer prognosis.
  • Strong association with Lynch syndrome (HNPCC).
  • FIGO staging is surgical; cornerstone of management.

Practice Questions: Endometrial Cancer

Test your understanding with these related questions

Risk of endometrial cancer is least in:

1 of 5

Flashcards: Endometrial Cancer

1/10

The prognosis of gynecologic tumor epidemiology can be remembered with the mnemonic: CEOs often go from best to worst as they get olderC_____ > Endometrial > Ovarian

TAP TO REVEAL ANSWER

The prognosis of gynecologic tumor epidemiology can be remembered with the mnemonic: CEOs often go from best to worst as they get olderC_____ > Endometrial > Ovarian

ervical

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial